Skin Manifestations of VEXAS Syndrome and Associated Genotypes
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2024.1657 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Isabella J Tan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. Hauptthemen laut MEDLINE: Genotype. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined genetic disease with an estimated prevalence of 1 in 4269 men older than 50 years and is marked by systemic inflammation, progressive bone marrow failure, and inflammatory cutaneous manifestations.
Objective
To define the spectrum of cutaneous manifestations in VEXAS syndrome and the association of these findings with clinical, genetic, and histological features. Design, Setting, and Participants This observational cohort study included data from 112 patients who were diagnosed with VEXAS-defining genetic variants in UBA1 between 2019 and 2023. Data were collected from medical record review or from patients with VEXAS directly evaluated at the National Institutes of Health in Bethesda, Maryland. Main Outcomes and Measures To define the spectrum of cutaneous manifestations in VEXAS in association with genetic, histological, and other clinical findings. A secondary outcome was cutaneous response to treatment in VEXAS.
Results
Among the 112 patients (median [range] age, 69 [39-79] years; 111 [99%] male), skin involvement was common (93 [83%]), and the most frequent presenting feature of disease (68 [61%]). Of 64 histopathologic reports available from 60 patients, predominant skin histopathologic findings were leukocytoclastic vasculitis (23 [36%]), neutrophilic dermatosis (22 [34%]), and perivascular dermatitis (19 [30%]). Distinct pathogenic genetic variants were associated with specific cutaneous manifestations. The p.Met41Leu variant was most frequently associated with neutrophilic dermal infiltrates (14 of 17 patients [82%]), often resembling histiocytoid Sweet syndrome. In contrast, the p.Met41Val variant was associated with vasculitic lesions (11 of 20 patients [55%]) with a mixed leukocytic infiltrate (17 of 20 patients [85%]). Oral prednisone improved skin manifestations in 67 of 73 patients (92%). Patients with VEXAS treated with anakinra frequently developed severe injection-site reactions (12 of 16 [75%]), including ulceration (2 of 12 [17%]) and abscess formation (1 of 12 [8%]). Conclusions and Relevance Results of this cohort study show that skin manifestations are a common and early manifestation of VEXAS syndrome. Genetic evaluation for VEXAS should be considered in older male patients with cutaneous vasculitis, neutrophilic dermatoses, or chondritis. Awareness of VEXAS among dermatologists is critical to facilitate early diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.
- University of Maryland School of Medicine, Baltimore.
- Cleveland Clinic Children's, Cleveland, Ohio.
- Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
- Department of Medicine and Center for Human Genetics and Genomics, NYU Grossman School of Medicine, New York University, New York.
Zitieren
APA
Tan, I. J., Ferrada, M. A., Ahmad, S., Fike, A., Quinn, K. A., Groarke, E. M., Beck, D. B., Allbritton, J., Castelo-Soccio, L., Young, N. S., Patel, B. A., Grayson, P. C., & Cowen, E. W. (2024). Skin Manifestations of VEXAS Syndrome and Associated Genotypes. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.1657
Vancouver
Tan IJ, Ferrada MA, Ahmad S, Fike A, Quinn KA, Groarke EM, et al. Skin Manifestations of VEXAS Syndrome and Associated Genotypes. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.1657
BibTeX
@article{Tan2024,
author = {Tan, Isabella J and Ferrada, Marcela A and Ahmad, Serene and Fike, Alice and Quinn, Kaitlin A and Groarke, Emma M and Beck, David B and Allbritton, Jill and Castelo-Soccio, Leslie and Young, Neal S and Patel, Bhavisha A and Grayson, Peter C and Cowen, Edward W},
title = {Skin Manifestations of VEXAS Syndrome and Associated Genotypes},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2024.1657}
}
EUVIMED